Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2019.01.056
Abstract: BACKGROUND Empagliflozin cardiac benefits in the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial cannot be explained exclusively by its antihyperglycemic activity. OBJECTIVES The hypothesis was that empagliflozin's cardiac… read more here.
Keywords: empagliflozin ameliorates; empagliflozin; left ventricular; heart failure ... See more keywords
Empagliflozin Ameliorates Preeclampsia and Reduces Postpartum Susceptibility to Adriamycin in a Mouse Model Induced by Angiotensin Receptor Agonistic Autoantibodies
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.826792
Abstract: Preeclampsia (PE) is the leading cause of maternal and perinatal morbidity and mortality and also is a risk factor for cardiovascular and kidney disease later in life. PE is associated with oversecretion of autoantibodies against… read more here.
Keywords: empagliflozin ameliorates; reduces postpartum; ameliorates preeclampsia; preeclampsia reduces ... See more keywords